Loading
A Chinese study with Geneplus-Beijing of a methylation blood test for eight cancers that found about eight in ten cancers, and about two in three stage I cancers, in people already diagnosed, at 99% specificity.
Luo and colleagues (Sun Yat-sen University Cancer Center with Geneplus-Beijing) built a targeted panel of 155,362 methylated CpG sites, read by enzyme-assisted (human TET) methylation sequencing rather than bisulphite conversion, for eight cancers: lung, breast, colorectum, liver, oesophagus, stomach, pancreas and ovary. In multicentre case-control cohorts (1,071 participants for training, 581 for validation and 824 for independent validation) the test had 99.0% specificity and 81.9% sensitivity in the independent validation set. Sensitivity was 65.5% at stage I and 79.7% at stage II. The top predicted cancer origin was right in 87.4% in independent validation (94.5% within the top two).
A stage I figure this high comes from a case-control design with known cancers; the same tests usually find far fewer early cancers when they meet people without symptoms.
Shares Cancer communications, Sun Yat-sen University Cancer Center.
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Shares Cell-free DNA methylation tests, Multi-cancer early detection (MCED).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/